DE60214134D1 - Modifizierte psma-liganden und deren verwendung - Google Patents

Modifizierte psma-liganden und deren verwendung

Info

Publication number
DE60214134D1
DE60214134D1 DE60214134T DE60214134T DE60214134D1 DE 60214134 D1 DE60214134 D1 DE 60214134D1 DE 60214134 T DE60214134 T DE 60214134T DE 60214134 T DE60214134 T DE 60214134T DE 60214134 D1 DE60214134 D1 DE 60214134D1
Authority
DE
Germany
Prior art keywords
psma ligands
modified psma
diagnosis
detection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60214134T
Other languages
English (en)
Other versions
DE60214134T2 (de
Inventor
V Frangioni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of DE60214134D1 publication Critical patent/DE60214134D1/de
Publication of DE60214134T2 publication Critical patent/DE60214134T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/005—Compounds of elements of Group 5 of the Periodic Table without metal-carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60214134T 2001-02-07 2002-02-07 Modifizierte psma-liganden und deren verwendung Expired - Fee Related DE60214134T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26705501P 2001-02-07 2001-02-07
US267055P 2001-02-07
PCT/US2002/021996 WO2002098885A1 (en) 2001-02-07 2002-02-07 Modified psma ligands and uses related thereto

Publications (2)

Publication Number Publication Date
DE60214134D1 true DE60214134D1 (de) 2006-10-05
DE60214134T2 DE60214134T2 (de) 2007-07-19

Family

ID=23017130

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214134T Expired - Fee Related DE60214134T2 (de) 2001-02-07 2002-02-07 Modifizierte psma-liganden und deren verwendung

Country Status (8)

Country Link
US (4) US6875886B2 (de)
EP (1) EP1363920B1 (de)
JP (1) JP2005507857A (de)
AT (1) ATE337011T1 (de)
CA (1) CA2436408A1 (de)
DE (1) DE60214134T2 (de)
MX (1) MXPA03007037A (de)
WO (1) WO2002098885A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP2008526979A (ja) * 2005-01-14 2008-07-24 サイトジェン コーポレーション 抗ｐｓｍａ抗体による併用癌治療法
EP1871810A2 (de) * 2005-04-08 2008-01-02 Cytogen Corporation Konjugierte anti-psma-antikörper
US20060264414A1 (en) * 2005-04-08 2006-11-23 The Board of Regents, University and Community College System of Nevada on behalf of the Fluorous 2,2'-bipyridines and fluorinated biphasic sysems for ligand design
WO2006121920A2 (en) * 2005-05-05 2006-11-16 Beth Israel Deaconess Medical Center, Inc. Micro-scale resonant devices and methods of use
EP1928503B1 (de) 2005-08-24 2012-10-03 ImmunoGen, Inc. Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
CA2626435A1 (en) * 2005-10-18 2007-05-10 Centre National De La Recherche Scientifique (Cnrs) Hypophosphorous acid derivatives and their therapeutical applications
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US7696185B2 (en) * 2006-03-14 2010-04-13 Cancer Targered Technology LLC Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
JP2009534309A (ja) * 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20110033379A1 (en) * 2006-08-29 2011-02-10 Frangioni John V Radio-labeled materials and methods of making and using the same
WO2008057437A2 (en) * 2006-11-03 2008-05-15 Purdue Research Foundation Ex vivo flow cytometry method and device
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2921482B1 (de) 2007-06-26 2018-09-05 The Johns Hopkins University Markierte hemmer des prostataspezifischen membranantigens (psma), biologische beurteilung und verwendung als bildgebungsmittel
JP2010535193A (ja) * 2007-08-01 2010-11-18 サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス チオホスフィン（チオホスホン）酸誘導体およびそれらの治療適用
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
FR2920086A1 (fr) 2007-08-24 2009-02-27 Univ Grenoble 1 Systeme et procede d'analyse pour une operation chirurgicale par endoscopie
EP2644594B1 (de) * 2007-09-28 2017-08-23 Pfizer Inc Krebszellen-Targeting unter Verwendung von Nanoteilchen
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2309991B1 (de) * 2008-06-16 2019-03-06 Pfizer Inc Therapeutische polymernanopartikel mit vincaalkaloiden sowie verfahren zu ihrer herstellung und verwendung
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
ES2462090T5 (es) * 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US20110288152A1 (en) * 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) * 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
SG173567A1 (en) 2009-02-06 2011-09-29 Beth Israel Hospital Charge-balanced imaging agents
US10493169B2 (en) 2009-02-06 2019-12-03 Beth Israel Deaconess Medical Center Use of charge-balanced imaging agents for determining renal function
CN102714296A (zh) 2009-05-19 2012-10-03 Aic布莱博公司 复合集电器及形成其的方法
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
CA2865282A1 (en) * 2012-02-24 2013-08-29 Cornell University Elevated psma identifies lethal prostate cancers
JP2015508903A (ja) * 2012-02-28 2015-03-23 コーネル ユニヴァーシティー 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ
BR112015005940A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
EA201890915A1 (ru) 2012-11-15 2018-09-28 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20170232119A1 (en) 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
AU2013383382B2 (en) 2013-03-15 2017-02-23 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
EP2842578B1 (de) * 2013-08-27 2018-06-27 GILUPI GmbH Diagnosevorrichtung zum nachweis von biomarkern
DE202014011600U1 (de) 2013-10-18 2023-05-31 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
AU2015315465B2 (en) * 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757694A3 (de) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostata-spezifisches Membranantigen
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6025345A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
JP2002515040A (ja) 1996-06-17 2002-05-21 ギルフォード・ファーマシューティカルズ・インコーポレイテッド Ｎａａｌａｄアーゼ阻害剤を用いる癌治療方法
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6348464B1 (en) 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
US7254409B2 (en) * 2000-04-14 2007-08-07 Ntt Docomo, Inc. Multicast service providing system, multicast service providing method, information distributor, radio terminal, and radio base station
WO2001092273A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
US6594498B1 (en) * 2000-08-14 2003-07-15 Vesuvius, Inc. Communique system for cellular communication networks
US6907023B2 (en) * 2000-08-14 2005-06-14 Vesuvius, Inc. Communique system with dynamic bandwidth allocation in cellular communication networks
US6954641B2 (en) * 2000-08-14 2005-10-11 Vesivius, Inc. Communique wireless subscriber device for a cellular communication network
US6741856B2 (en) * 2000-08-14 2004-05-25 Vesuvius Inc. Communique system for virtual private narrowcasts in cellular communication networks
US7024200B2 (en) * 2000-08-14 2006-04-04 Vesuvius, Inc. Communique system with active feedback for cellular communication networks
US6829486B2 (en) * 2000-08-14 2004-12-07 Vesuvius Communique system for combined cellular and wireline communication networks
US6687498B2 (en) * 2000-08-14 2004-02-03 Vesuvius Inc. Communique system with noncontiguous communique coverage areas in cellular communication networks
US6681115B1 (en) * 2000-08-14 2004-01-20 Vesuvius Inc. Communique subscriber handoff between a narrowcast cellular communication network and a point-to-point cellular communication network
US6684076B2 (en) * 2000-08-14 2004-01-27 Vesuvius Inc. Communique system with hierarchical communique coverage areas in cellular communication networks
WO2002038190A2 (en) * 2000-10-27 2002-05-16 Beth Israel Deaconess Medical Center Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
WO2002057222A2 (en) 2001-01-17 2002-07-25 Guilford Pharmaceuticals Inc. Thiol-based naaladase inhibitors

Also Published As

Publication number Publication date
US20050245486A1 (en) 2005-11-03
US20040110723A1 (en) 2004-06-10
US6875886B2 (en) 2005-04-05
DE60214134T2 (de) 2007-07-19
JP2005507857A (ja) 2005-03-24
EP1363920B1 (de) 2006-08-23
WO2002098885A1 (en) 2002-12-12
ATE337011T1 (de) 2006-09-15
MXPA03007037A (es) 2003-11-18
CA2436408A1 (en) 2002-12-12
US20080175789A1 (en) 2008-07-24
EP1363920A4 (de) 2004-04-21
US20040229845A1 (en) 2004-11-18
EP1363920A1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
IL153052A0 (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
DE69936049D1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
ATE489108T1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
WO2003104410A3 (en) ENZYMES
WO2003033731A3 (en) Methods for detecting ovarian cancer
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2003093794A3 (en) Methods for discovering tumor biomarkers and diagnosing tumors
WO2008104805A3 (en) Proteins
RS20100249A (en) CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE
DE50205750D1 (de) Liganden für den nachweis von prionen
MX2007005501A (es) Asociacion tumoral de mieloide de lectina-1 asociada a dap12 y metodos.
ATE404208T1 (de) Uridin-therapie für patienten mit erhöhten purin- werten
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee